Billionaire hedge fund manager David Tepper, of Appaloosa Management, bought 7.8 million shares of Boston Scientific stock during the 4th quarter, according to regulatory filings, for a stake with a market value of $41.6 million as of Dec. 31.
Buyout chatter pushed shares of Shire plc (FTSE:SHP) up nearly 2% in London yesterday and added 1.4% on Wall Street.
Thoratec (NSDQ:THOR) shares are up more than 11% today after the heart pump maker put mid-double-digit profit growth numbers on the board for the 4th quarter and full-year 2011.
The Pleasanton, Calif.-based cardiac assist device maker logged profits of $15.3 million, or 25 cents per diluted share, on sales of $109.4 million for the 3 months ended Dec. 31, 2011. That’s a 46.4% bottom-line gain and a top-line boost of 12.1%, compared with profits of $10.5 million, or 17 cents diluted EPS, on sales of $97.6 million during Q4 2010.
Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.
NuVasive (NSDQ:NUVA) is paying dearly for a $101 million judgment against it in a patent war with Medtronic (NYSE:MDT), as Wall Street investors pare nearly 14 percent from its share price today after the release of its third-quarter earnings.
Investors pounded NuVasive Inc. today, sending share prices down nearly 14 percent as of about noon, after the spine surgery company released its Wall-Street-beating third-quarter results.
Bernard Gordon, who founded medical imaging giant Analogic Corp. (NSDQ:ALOG) in 1964, is accusing the company of deliberately interfering with acquisitions of his new firm, NeuroLogica Corp.
In a lawsuit filed in the U.S. District Court for Massachusetts, NeuroLogica and co-plaintiffs Gordon and two other NeuroLogica executives accuse Analogic of seeking to prevent another, un-named company from acquiring NeuroLogica in a bid to force a below-market buyout in its own favor.
MASSDEVICE ON CALL — The Mass. Life Sciences Center, a quasi-public agency that oversees state dollars allocated toward increasing the life sciences industry’s footprint in the Bay State, doled out another $3.8 million in “accelerator” loans.
The program is designed to provide a boost to early-stage life science companies that the center’s scientific advisory board deems to have a high potential for commercialization, rapid growth and the ability to raise substantial capital.